Growth Metrics

Edwards Lifesciences (EW) Asset Writedowns and Impairment (2018 - 2025)

Edwards Lifesciences has reported Asset Writedowns and Impairment over the past 3 years, most recently at $146.9 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $146.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $234.0 million (changed N/A YoY), and the annual figure for FY2025 was $186.9 million, changed.
  • Asset Writedowns and Impairment for Q4 2025 was $146.9 million at Edwards Lifesciences, up from $40.0 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for EW hit a ceiling of $146.9 million in Q4 2025 and a floor of $40.0 million in Q3 2025.